You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
Under the arrangement, Rosetta would offer physicians the option to have thyroid samples analyzed by FNApath, with indeterminate samples tested with its microRNA assay.
The medical policy update makes the unnamed insurer the first commercial plan to cover ThyraMIR, a microRNA gene expression classifier launched earlier this year.
The company said its revenues rose on increased sales of its Afirma gene expression classifier tests, which benefited from increased insurance coverage.
Aetna is the first major commercial insurer to cover Interpace's ThyGenX and brings the total number of covered lives for it to more than 100 million.
The test differentiates benign thyroid nodules from cancerous ones.
The increased revenues were driven by a 30 percent uptick in Afirma gene expression classifier test volume.
In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.
The firm also disclosed that it has paid $1.2 million in severance and bonuses related to its acquisition of Allegro Diagnostics.
Kura's clinical collaborators will conduct NGS analysis to identify patients with HRAS mutations and who may also respond to tipifarnib.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.